Market Overview

Generex Biotechnology to Present Overview of Immuno-Oncology Development Program at Summit in Boston, MA


EVP R&D to be a Presenting Panelist

Novel Therapeutics in Cancer Immunotherapy at the
Immuno-Oncology Investing & Partnering Forum on August 30
at 1:30 PM

Generex Biotechnology Corporation (
is pleased to announce that Richard Purcell, the Company's Executive
Vice President of Research & Development will participate in a panel
discussion at the Cambridge Healthtech Institute's Immuno-Oncology
Summit at the Seaport World Trade Center in Boston, MA (
on August 30, 2018. The panel discussion will focus on current trends
and future prospects for immunotherapy in the treatment of cancer.
Additionally, Mr. Purcell will provide an overview of the relaunched
clinical development program of the HER2/neu immunotherapeutic vaccine,
AE37, together with strategies to advance the proprietary Ii-Key
technology under development at the Company's wholly-owned subsidiary,
Antigen Express, Inc. (

"The introduction of checkpoint inhibitors has been revolutionary in the
practice of clinical oncology, but is only effective in roughly 30% of
patients across a variety of cancers," said Mr. Purcell. "The
complementary mechanism of action of AE37 (T-cell activation), and
encouraging results obtained in triple negative breast cancer patients,
strongly suggest that the combined use of AE37 with pembolizumab
(Keytruda®) will provide significantly greater efficacy than either

The Immuno-Oncology Investing & Partnering Forum is taking place on
Thursday, August 30th and the session Novel
Therapeutics in Cancer Immunotherapy
will take place at 1:30 pm EDT
and consist of company presentations followed by Q&A with the audience.
The conference is taking place at the Seaport World Trade Center in
Boston, MA, and the session room is Beacon Hill 1.

Cautionary Note Regarding Forward-Looking Statements

This release and oral statements made from time to time by Generex
representatives in respect of the same subject matter may contain
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. These statements can be
identified by introductory words such as "expects," "plan," "believes,"
"will," "achieve," "anticipate," "would," "should," "subject to" or
words of similar meaning, and by the fact that they do not relate
strictly to historical or current facts. Forward-looking statements
frequently are used in discussing potential product applications,
potential collaborations, product development activities, clinical
studies, regulatory submissions and approvals, and similar operating
matters. Many factors may cause actual results to differ from
forward-looking statements, including inaccurate assumptions and a broad
variety of risks and uncertainties, some of which are known and others
of which are not. Known risks and uncertainties include those identified
from time to time in the reports filed by Generex with the Securities
and Exchange Commission, which should be considered together with any
forward-looking statement. No forward-looking statement is a guarantee
of future results or events, and one should avoid placing undue reliance
on such statements. Generex undertakes no obligation to update publicly
any forward-looking statements, whether as a result of new information,
future events or otherwise.
Generex claims the protection of the
safe harbor for forward-looking statements that is contained in the
Private Securities Litigation Reform Act.

View Comments and Join the Discussion!